Meloxicam/Rizatriptan

- Axsome Therapeutics has entered into a $570 million credit facility with Blackstone, expanding their available credit by over $200 million while significantly reducing capital costs.

- ADMA Biologics has received FDA clearance for a yield enhancement process that is expected to significantly improve production margins for its immunoglobulin products starting in 2026.

- Landmark clinical trial demonstrates significant visual improvements in all four young children treated with MeiraGTX's rAAV8.hRKp.AIPL1 gene therapy for Leber congenital amaurosis 4 retinal dystrophy.

- Axsome Therapeutics achieved remarkable financial performance in 2024, with total net product revenue reaching $385.7 million, representing an 88% year-over-year growth driven by strong Auvelity and Sunosi sales.

- The FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults, offering a novel multi-mechanistic approach.